Drug Discovery

SGS picks 60% stake in Nutrasource

Swiss company SGS has purchased a majority stake in Nutrasource Pharmaceutical and Nutraceutical Services as well as its subsidiaries (Nutrasource).

Sandoz, Just – Evotec Biologics tie up to develop multiple biosimilars

Sandoz and Evotec’s Seattle-based subsidiary, Just - Evotec Biologics have reached a multi-year, long-term tech alliance to develop and manufacture multiple biosimilars.

Life Bio, Forge to develop gene therapies for aging-linked diseases

Life Biosciences has announced a cGMP manufacturing collaboration with Forge Biologics for advancing the development of new gene therapies to treat aging-related diseases.

Neogap, Cellerys partner for study of multiple sclerosis therapy

Biopharmaceutical company Neogap Therapeutics has partnered with Swiss company Cellerys for a Phase II study of the latter’s RED4MS therapy for multiple sclerosis.

Hansa Biopharma enters into collaboration with Genethon

Swedish biotech company Hansa Biopharma has entered a research and development collaboration with Genethon.

Stablix, Vertex partner to develop targeted protein stabilisation therapies

Biopharmaceutical company Stablix and Vertex Pharmaceuticals have joined forces to discover and develop targeted protein stabilisation (TPS) therapies.

Boehringer Ingelheim opens new biotechnology R&D centre in Germany

Boehringer Ingelheim has opened its new advanced Biologicals Development Center (BDC) in Biberach an der Riß, Germany.

BullFrog AI, Sage Group partner to develop oncology assets

Digital technology company BullFrog AI and Sage Group have entered into a strategic partnership to develop oncology assets.

Talem, Xyphos sign agreement for potential cancer therapeutic candidates

ImmunoPrecise Antibodies (IPA) subsidiary, Talem Therapeutics has entered into a research collaboration and licence option agreement with Astellas Pharma’s wholly-owned subsidiary, Xyphos Biosciences.